Release Notes
4/28/2026: Release v2.56.1
Hepatitis B
Transitioned from a Hep B 3-dose Newborn Series and a Hep B 3-dose Child/Adolescent Series to a modified Hep B 3-dose Child/Adolescent Series.
Modified the Hep B 3-dose Child/Adolescent Series as indicated:
Series starts at birth instead of 28 days
Added CVX 189 and CVX 220 to Valid CVX Code Per Dose 1 for this Series
Added Dose 1 to 3 interval
Added Series Special Rules
Adolescent Rules: Series Complete After 2 Doses
Switch to Hep B 4-dose Child/Adolescent Series if Target Dose 3 Does Not Meet Absolute Minimum Interval or Series Absolute Minimum Age
Added support for a new Hep B 4-dose Child/Adolescent Series.
Move the Atkinson rule from a Hepatitis B General Rule to a special rule in the Adult 3-dose Series.
Updated the Series Selection Rules that when a dose of CVX 189 is administered at >=19y and there are no other doses on record, select the Hep B 2-dose Adult Series instead of Hep B 3-dose Adult Series.
Polio
Added support for Poliovirus, inactivated, fractional-dose (fIPV) (Non-US; Non-US polio vaccine administered since 2016), including:
New series: Polio fIPV Series
New vaccine code: CVX 324
Updated series selection logic to account for the new series.
Updated CVX Code Special Rules
Modified Rule for CVX 178 and CVX 179 to consider these shots as inadvertent.
Added Rule for CVX 02 and CVX 182 to replace the OPV Rule in the Polio 4-dose Series - Series Special Rules and to treat CVX 182 as inadvertent if administered >= 4/1/2016.
Removed the OPV Rule in the Polio 4-dose Series - Series Special Rules and replaced with CVX Code Specific Rules: Rule for CVX 02 and CVX 182.
Updated Rules Based on Patient's Age for patient’s >= 18 years old who have completed the series and where the evaluation is Accepted / EXTRA_DOSE, to apply the evaluation of Accepted / EXTRA_DOSE regardless of the CVX Code Specific Rules - Rule for CVX 178 and CVX 179 and Rule for CVX 02 and CVX 182.
Core Service Updates
Added experimental support for the return of series and season as optional evaluation and forecasting outputs. The output format of the series and seasons may be revised in a future release. When the
output-series-informationproperty is set to true, ICE will return the selected series/seasons for substance administration events and forecasts. Note: This feature introduces new related clinical statements within substance administration events and administration proposals. Tools that parse ICE responses may require modification to properly handle the presence of these new elements when these features are enabled. Additional details regarding this feature are available at Series/Season Display Selection and Number of Doses Remaining.
ICE Implementation Guide Codes
The ICE Implementation Guide Codes Sheet was updated to reflect the following:
Vaccines: new CVX 324
Series: new Hep B 4-dose Child/Adolescent Series, new Polio fIPV Series, removed Hep B 3-dose Newborn Series
Seasons: new tab indicating seasons as coded values
3/28/2026: Release v2.55.1
COVID-19 Pandemic
For shots prior to 9/12/2023 only, relaxes the evaluation logic for CVX 229 and CVX 230 vaccinations to potentially be marked Valid.
Do not restrict CVX 229 or CVX 230 from potentially being marked Valid when administered prior to 4/19/2023.
Allow CVX 230 to potentially be marked Valid if administered in the primary series (as opposed to just as a booster dose).
Hepatitis A
Added support for a new Twinrix series: Hep A 4-dose Accelerated Twinrix Series.
Recommend at the CVX level (CVX 104).
New supplemental text returned for the recommendation of target dose 4. Descriptive text: "If the Twinrix vaccine (CVX 104) is not available, another age-appropriate Hep A vaccine may be administered."
Updated series selection logic to account for the new series.
Added alignment with Hepatitis B to coordinate Twinrix series recommendations if appropriate.
E.g., Updated the Hep A 3-dose Series to recommended at the CVX level (CVX 104) when aligned with the Hep B 3-dose Twinrix series at the same dose number and recommendation date. Supplemental text descriptive text returned in this case: "If the Twinrix vaccine (CVX 104) is not available, another age-appropriate Hep A vaccine may be administered."
Hep A 2-dose Series: Added special rules to accommodate a switch to the Hep A 3-dose Series in certain circumstances.
Hep A 3-dose Series: Added Dose 1 to Dose 3 intervals: absolute minimum interval (6 months - 4 days), minimum interval (6 months), and recommended interval (6 months).
Hepatitis B
Added support for two new Twinrix series: Hep B 3-dose Twinrix Series and Hep B 4-dose Accelerated Twinrix Series.
Both series recommend at the CVX level (CVX 104).
New supplemental text returned along with a recommendation in the Hep B 3-dose Twinrix Series. Descriptive text: "If the Twinrix vaccine (CVX 104) is not available, another adult Hep B vaccine may be administered."
Updated series selection logic to account for the two new series.
Added alignment with Hepatitis A to coordinate Twinrix series recommendations if appropriate.
Polio
Updated support for adult polio vaccination:
For patients >= 18 years with polio history, but incomplete for the series: Updated the recommendation from Conditional / HIGH_RISK to Recommended.
For patients >= 18 years with no polio history: Updated the Conditional / HIGH_RISK recommendation to include SUPPLEMENTAL_TEXT, Descriptive text: "Unless there are specific reasons to believe they were not vaccinated, most adults who were born and raised in the United States can assume they were vaccinated against polio as children. Refer to ACIP for additional information."
For patients >= 18 years complete for polio: Added support for a recommendation of Conditional / COMPLETE_HIGH_RISK and SUPPLEMENTAL_TEXT; Descriptive text: "Adults who completed their polio vaccination but who are at increased risk of exposure to poliovirus may receive one lifetime IPV booster. Refer to ACIP for additional information." For these patients, the first shot administered after series completion will be evaluated as Valid / BOOSTER_DOSE (new Evaluation Reason Code).
Added support to return supplemental text along with the evaluation of CVX 89 (Polio, unspecified formulation (NOS)) if administered >= 4/1/2016, to alert users that additional protection may be needed. Descriptive text: “CVX 89 represents an unspecified formulation vaccine. Trivalent oral polio vaccine ceased to be used globally in April 2016. If the patient received bivalent or monovalent oral polio vaccine (bOPV or mOPV), additional protection is needed.”
4-dose Series Exception Rules
Added support for the grace period in the evaluation of dose 3 (at >= 4 years - 4 days).
Addressed an issue where, after an invalid target dose 3, ICE was forecasting target dose 3 at an interval of 28 days rather than 6 months.
Core Service Updates
Service start up time is substantially faster.
Supporting data has been converted from XML to YAML format, which enables runtime values to be changed via start up parameters. Documentation about this feature is forthcoming.
Supporting data (YAML files) are read in on service start up so that they do not have to be initialized when the first request comes in.
ICE Implementation Guide Codes
The ICE Implementation Guide Codes Sheet was updated to reflect the following additions:
Evaluation reason code: BOOSTER_DOSE
Series: Hep A 4-dose Accelerated Twinrix Series, Hep B 3-dose Twinrix Series, and Hep B 4-dose Accelerated Twinrix Series
Evaluation Supplemental Text: Polio supplemental text
Recommendation Supplemental Text: Hepatitis A, Hepatitis B, and Polio supplemental text
Clinical Guidelines Documentation
A new Clinical Guidelines wiki page indicates ICE Default Schedule alignment with schedule authority clinical guidelines, both overall and by vaccine group.
Additionally, an info box was also added to each vaccine group wiki page indicating rule alignment with clinical guidelines.
CDS Insight
A new tool, CDS Insight, is now available to support demonstration and testing of the ICE service; check out this tool to see these ICE updates in action. The CDS Insight: Immunization CDS module serves as a front-end interface that allows users to interact with HLN Consulting’s locally-hosted version of the most recent publicly available instance of ICE. The module allows users to simulate patient scenarios and receive immunization evaluations and recommendations based on the latest ICE rules. CDS Insight will replace the ICE Client application.
3/2/2026: Release v2.53.2
COVID-19 Seasonal
2025-2026 Season, in the Seasonal 1-dose Series (2-64 years) and the Seasonal 2-dose Series (>= 65 years):
Added to the Evaluation Intervals to Target Dose 1 special rule to address the absolute minimum interval from the most recent CVX 313 to a non-CVX 313 shot.
Addressed a series selection issue, where in limited scenarios, ICE was selecting the incorrect series.
2025-2026 Season, in the Seasonal 2-dose COVID-19 Series (< 2 years): Updated dose numbering to ensure ICE returns the correct dose number when target doses span multiple seasons.
Core Service Update
Addressed an issue with the Dose Override feature whereby the interpretation element was not being returned when the request indicates that the shot should be marked as Invalid. (Only applicable if the enable-dose-override-feature is enabled.)
2/4/2026: Release v2.53.1
COVID-19 Seasonal
2025-2026 Season, in the Seasonal 2-dose COVID-19 Series (< 2 years): Addressed an issue specific to the special rule, Skip Dose Rules, 1 Dose of Moderna on Record Prior to Season Start, where ICE was enforcing a 24-day absolute minimum interval from a prior season invalid Pfizer to a new season target dose rather than a 17-day interval.
Cholera
Added support for the Cholera vaccine group, including:
New series: Cholera Risk 1-dose Series
New vaccine code: CVX 174
Japanese Encephalitis
Added support for the Japanese Encephalitis vaccine group, including:
New series:
JE-VC Risk 2-dose Series
JE-VC Risk 2-dose Accelerated Series (18-65 years)
New vaccine code: CVX 134
Typhoid
Added support for the Typhoid vaccine group, including:
New series: Typhoid Risk Series
New vaccine codes: CVX 25, CVX 101
Yellow Fever
Added support for the Yellow Fever vaccine group, including:
New series: Yellow Fever Risk Series
New vaccine codes: CVX 37, CVX 183, CVX 184
Core Service Update
Improved vaccine group inclusion/exclusion options in the application.yml file or via environment variable. Specifically:
An ICE instance can be configured with a full list of vaccine groups to support via the inclusion property, or via the exclusion property, all vaccine groups not to support.
Out of the box, ICE supports the same set of vaccine groups as in the last release. That is, cholera, japanese encephalitis, typhoid and yellow fever vaccine groups must be individually enabled.
Ability to specify a boolean property in each vaccine group XML configuration if a vaccine group is "routine" or "non-routine".
The ICE Implementation Guide and ICE Implementation Guide Codes Sheet have both been updated to reflect additions related to the addition of the four new travel/non-routine vaccine groups: cholera, Japanese Encephalitis, Typhoid, and Yellow Fever, including new Vaccines, Vaccine Groups, Series, a new Recommendation Reason code (BELOW_REC_AGE_SERIES) and Supplemental Text.
1/14/2026: Release v2.52.2
Core Service Updates
Fix for vaccine group exclusions not working. 2.52.2 release distributed to Docker Hub only.
12/29/2025: Release v2.52.1
COVID-19 Seasonal
2025-2026 Season:
In the Seasonal 2-dose COVID-19 Series (< 2 years):
Updated intervals from a prior season Pfizer shot to a target dose in the new season, for patients < 2 years as per updated American Academy of Pediatrics guidance. Specifically, updated intervals from a prior season Pfizer, Novavax, or unspecified to a target dose Moderna in the new season for patients < 2 years, from 24/28 days to 17/21 days.
Addressed a gap in the logic to ensure a forecasting interval between a prior season invalid shot and a target dose in the new season for patients < 2 years.
Core Service Updates
Upgraded from Java 21 to Java 25.
Upgraded the rules engine from Drools 7 to Drools 10.
Upgraded to OpenCDS 7.0.1.
Added support to run with Spring Boot as well as Tomcat 11 or Tomcat 10.
Note: The installation instructions have been updated given the core service updates. There are no ICE Implementation Guide Codes sheet changes for this release.
11/18/2025: Release v2.51.1
COVID-19 Seasonal
2025-2026 Season: Added support for the 2025-2026 season, with a season start date of 8/27/2025. The 2025-2026 season rules are aligned with American Academy of Pediatrics recommendations for patients through age 18 years and American Academy of Family Physicians recommendations for children/adolescents and adults. The medical society recommendations indicate individual decision-making for a subset of the population, specifically, previously vaccinated children aged 2 through 18 years not at increased risk, rather than for all individuals aged 6 months and older as indicated by ACIP/CDC. For the 2025-2026 season updates include:
Three new 2025-2026 season series:
Seasonal 2-dose COVID-19 Series (< 2 years)
Seasonal 1-dose COVID-19 Series (2 - 64 years)
Seasonal 2-dose COVID-19 Series (>= 65 years)
Patients age 2 years - < 19 years with >= 1 dose of COVID-19 on record prior to the season start date and no in-season doses on record will have a recommendation of Conditional / HIGH_RISK, CLINICAL_PATIENT_DISCRETION; ICE will also return forecasting dates (earliest date, recommended date) along with the Conditional recommendation.
Added support for CVX 334, COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL, Moderna (mNEXSPIKE, 12+ yrs).
2024 - 2025 Season: Added an end date of 8/26/2025 for the 2024-2025 COVID-19 season.
Added support for CVX start dates and CVX end dates for seasonal COVID-19 vaccines.
Updated CVX names for seasonal COVID-19 vaccines to the following:
CVX 308: COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL, Pfizer (Comirnaty, 6 mos-4 yrs)
CVX 309: COVID-19, mRNA, LNP-S, PF, tri-sucrose, 30 mcg/0.3 mL, Pfizer (Comirnaty, 12+ yrs)
CVX 310: COVID-19, mRNA, LNP-S, PF, tri-sucrose, 10 mcg/0.3 mL, Pfizer (Comirnaty, 5-11 yrs)
CVX 311: COVID-19, mRNA, LNP-S, PF, 25mcg/0.25 mL, Moderna (Spikevax, 6 mos-11 yrs)
CVX 312: COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL, Moderna (Spikevax, 12+ yrs)
CVX 313: COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL, Novavax (12+ yrs)
COVID-19 Pandemic
Added CVX start date of 12/11/2020 for CVX 211 and CVX 213.
Mpox
Updated vaccine group name from "Orthopoxvirus Vaccine Group - May 2022 Emergency Use Authorization (EUA) for Mpox" to "Mpox Vaccine Group".
Replaced "Orthopoxvirus" references with "Mpox".
Removed "May 2022 Emergency Use Authorization (EUA)" references.
Added support for CVX 325 (vaccinia (smallpox, mpox), unspecified (NOS)).
Removed live vaccine interval for CVX 206. The ICE General Rule "Live Vaccine Interval" rule does NOT apply for CVX 206. CVX 206 does not replicate and for the purposes of timing and spacing recommendations behaves like non-live vaccines.
The CVX code specific rule to not enforce the live vaccine interval in the evaluation of CVX 75 and CVX 105 was removed.
Updated the CVX 206 name from "Vaccinia, smallpox mpox vaccine live, PF (JYNNEOS)" to “vaccinia, smallpox mpox vaccine live, PF, SQ or ID injection".
Updated series names to reflect the naming transition from orthopoxvirus to mpox.
General Rules
Added two new general rules: Evaluation of Shots Prior to the CVX Start Date and Evaluation of Shots After the CVX End Date. These rules are currently used in Seasonal and Pandemic COVID-19.
Updated mpox-related references and rules as needed to align with mpox vaccine group changes noted above.
Core Service Update
Updated the ICE service from Java 17 to Java 21. The Java update requires users who download the zipfile distribution to upgrade to Java 21. The service can now be used with either Tomcat 10 or Tomcat 11 (previously, Tomcat 11 was not supported).
An upcoming release will transition ICE from Drools 7 to Drools 10.
The ICE Implementation Guide Codes Sheet was updated to reflect the vaccine additions and name updates, new COVID-19 series for the 2025-2026 season, and the additional SUPPLEMENTAL_TEXT, descriptive text used in the 2025-2026 COVID-19 season.
9/2/2025: Release v2.48.1
Influenza
Added support for new CVX 333 (Influenza, live, intranasal, self/caregiver admin).
Added support for new CVX 331 (Influenza, Southern Hemisphere, trivalent, preservative free).
Updated CVX 201 name to reflect ‘quadrivalent’ (Influenza, Southern Hemisphere, quadrivalent, preservative free).
Modified Immunization Series and Selection Rules name to reflect the 2025 - 2026 Influenza Vaccine Season (wiki updates only, no logic changes).
Modified Influenza 1-dose Series Special Rule.
RSV
Added support for CVX 332 (RSV, mAb, 0.7 mL, age 0 - < 8 mos. (clesrovimab)).
Updated CVX 306 name to reflect 'nirsevimab' (RSV, mAb, 0.5 mL, age 0 - < 8 mos. (nirsevimab)).
Updated CVX 307 name to reflect 'nirsevimab' (RSV, mAb, 1 mL, age 0 - 19 mos. (nirsevimab)).
Lowered the age for the Conditional risk-based recommendation for adult RSV from 60 years to 50 years.
Added a rule to ensure ICE does not forecast infant RSV before RSV was recommended.
6/27/2025: Release v2.47.1
Hepatitis A
Modified the series selection rules to limit selection of the 3-dose series to when CVX 104 (Twinrix) is administered to an adult patient as dose 1 and/or dose. When Twinrix is not used, ICE will evaluate and forecast in the 2-dose series, where a 6-month interval is required between doses.
Added absolute minimum ages and absolute maximum ages to Hepatitis A vaccines. The addition of the absolute maximum age will invalidate pediatric formulations of the vaccines when given to patients 19 years and older, in line with recommendations to repeat the dose. A new CVX-code rule was added so no interval is required between an invalid shot given above the vaccine absolute maximum age and the next target dose.
Modified the Hep A 2-dose series: Modified series special rules to allow a grace period between dose 1 and target dose 2 (when invalid between).
Modified the Hep A 3-dose series: changes to the absolute minimum age, minimum age, and routine age for target dose 1, added series special rule for Hep A 3-dose series to when CVX 104 (Twinrix) has no maximum age for the Hep A vaccine component CVX 83, added a series special rule for Hep A 3-dose series to when a third dose is not needed.
Hib
Updated the booster dose handling of CVX 50 in the Hib OMP series.
Updated the implementation to support CVX 50 as a valid dose for target dose 3 in the Hib OMP series.
Added a special rule to clarify handling of CVX 50 in the Hib OMP series.
MMR
Updated the evaluation of MMR at 6 - 11 months from Invalid to Accepted, given MMR may be given at this age for high-risk patients.
Updated the dose 1 and dose 2 absolute minimum age to months/years instead of days (Dose 1: 361 days to 1 year - 4 days; Dose 2: 389 days updated to 13 months - 4 days).
Orthopoxvirus
Updated the CVX 75 name from “vaccinia (smallpox) vaccine (ACAM2000)” to “Vaccinia (smallpox, mpox), live”, in alignment with CDC CVX name updates.
Pneumococcal
Updated adult logic to align with the latest guidelines, including lowering the recommended age for the first adult vaccination from 65 years to 50 years.
Added support for CVX 327 (PCV21) and CVX 177 (PCV10).
Added PCV20 to the childhood series.
Improvements to the handling of duplicate pneumococcal shots recorded on the same day.
For the zip file distribution only: added a new property, disable_output_earliest_and_overdue_dates_for_pneumococcal_adult_series. If set to "Y", ICE will not output the earliest and overdue dates for the Adult Pneumococcal Series. By default, this setting is disabled.
Polio
Updated the CVX 02 name from “OPV” to “OPV, trivalent” for additional clarification, in alignment with the CDC CVX description.
Updated the CVX 89 name from “Polio, unspecified formulation” to “Polio, unspecified formulation (NOS)” for additional clarification.
There were no logic updates associated with these vaccines.
RSV
Updated recommendation for patients age 8 months - < 20 months old who completed their infant series from Conditional / HIGH_RISK to Conditional / COMPLETE_HIGH_RISK to support identification of children in this age range who completed the RSV infant series as compared to those who did not.
General Rule: Live Vaccine Interval
Updated to ensure enforcement of a 28-day absolute minimum interval between a Varicella and MMRV as well as an MMR and MMRV.
The ICE Implementation Guide Codes Sheet was updated to reflect the polio and orthopoxvirus vaccine name updates; the addition of CVX 327, and CVX 177; the addition of new recommendation reason codes: ADMINISTER_PCV15_PCV20_OR_PCV21, and ADMINISTER_PCV20_OR_PCV21; and modified and new SUPPLEMENTAL_TEXT, descriptive text used in pneumococcal.
4/26/2025: Release v2.46.1
Meningococcal B
Added support for the updated dosing intervals for MenB-4C (Bexsero). ICE now supports the previous MenB-4C schedule and the updated MenB-4C schedule as of October 25, 2024. As part of this update, the following changes were made:
Updates to the MenB 4C 2-dose Series to consider vaccine administration date in series age and interval parameters.
Addition of a new MenB 4C 3-dose Series.
Updates to the Two Shots, Same Vaccine Group, Same Day Exception Rules for Meningococcal B.
Added support for CVX 328, Meningococcal MenABCWY (Penmenvy).
Meningococcal
Added support for CVX 328, Meningococcal MenABCWY (Penmenvy).
Updated the CVX 108 vaccine name from "Meningococcal, unspecified formulation" to "Meningococcal ACWY, unspecified formulation" for additional clarity in alignment with the CDC CVX name (wiki update only; no logic changes for CVX 108).
COVID-19 - Seasonal
Addressed an issue to ensure a vaccine group-level recommendation (rather than CVX-level recommendation) when indicated in the rules for patients in Seasonal COVID-19 < 5 years series. (For patients in an < 5 years series, ICE returns a vaccine group-level recommendation if the patient is >= 5 years as of the recommended date or the evaluation date, and either the recommendation date or the evaluation date is >= 8 weeks from the last administered COVID-19 shot.)
Addressed an issue that, in rare circumstances, ICE did not properly select a series in the 2024-2025 season when both the 2023-2024 and 2024-2025 series were completed, resulting in a processing error.
The ICE Implementation Guide Codes Sheet was updated to reflect the addition of a Meningococcal B series, the vaccine name change for CVX 108, the new CVX 328, and the addition of supplemental text descriptive text used in Meningococcal B.
2/18/2025: Release v2.45.2
HPV
Fixes an issue discovered in v2.45.1 where the HPV minimum age was changed from 9 years to 11 years. This was an inadvertent change in the files included in the final v2.45.1 release. Version 2.45.2 resets the HPV minimum age to 9 years.
2/17/2025: Release v2.45.1
COVID-19
Added support for the 2023 - 2024 season additional dose recommendation for patients ages 65 years and older.
Added support for the 2024 - 2025 season, including the new season start date of 8/22/2024 and the 2024 - 2025 season additional dose recommendation for patients ages 65 years and older.
Starting with the 2024 - 2025 season, CVX 308 can no longer complete the Pfizer series for patients who transition to age 5 years during an initial vaccination series.
Cross-season changes to support alignment with updated guidance:
Introduced an interval for shots administered below the series absolute minimum age in the < 5 years series.
Introduced a longer interval between an updated Novavax (CVX 313) and an mRNA vaccine for patients 12 years and older.
Introduced a longer interval from COVID-19 shots that do not count towards U.S. vaccination and the updated COVID-19 vaccines.
Modified the series selection rules for selecting a < 5 years series, to consider valid doses only in series selection. Additional special rule in the < 5 years Pfizer Series to ensure appropriate intervals between Pfizer and non-Pfizer shots.
Modified the series selection rules for selecting the Novavax series or >= 5 years series, to consider patient age and dose 2 in series selection.
Modified the rules to recommend at the CVX level vs group level, to recommend at the CVX level in the Moderna and Pfizer < 5 years series in certain circumstances.
Note, for all COVID-19 vaccine seasons, COVID-19 shots administered are evaluated based on the rules in effect as of the shot administration date, and COVID-19 recommendations are based on the rules in effect as of the evaluation date.
Hepatitis B
Addressed an issue in the series selection implementation that resulted in the Newborn Series rather than the Child/Adolescent Series being selected under certain circumstances.
Addressed an issue in the series selection implementation that resulted in the Adult Series rather than the Child/Adolescent Series being selected under certain circumstances.
Hib
Added CVX 132 to the Hib 4-dose series in the implementation files (no wiki changes; CVX 132 was already represented in the Hib 4-dose series on the wiki).
RSV
Updated the display name for CVX 307 in the configuration files (no wiki changes).
Removed the Evaluation of Shots Prior to 10/1/2023 RSV general rule. Replaced with new rules to support validation of infant RSV CVX codes starting on 8/3/2023 and to support validation of adult or otherwise unspeciifed RSV CVX codes starting on 6/21/2023.
Updated supplemental text to remove special characters (en dash and apostrophe).
Zoster
Updated the implementation of the minimum interval between a CVX 121 or CVX 188 to a CVX 187 to 56 days rather than 28 days, to align with the wiki rules.
Additional Updates
Addressed an issue with supplemental text, where, in some circumstances, supplemental text associated with one vaccine group appeared in the forecast output for a different vaccine group.
The ICE Implementation Guide was updated to reflect the changes to the RSV supplemental text.
11/01/2024: Release v2.44.1 / v1.44.1
DTP Update
Added a minimum recommended age of 7 years in the DTP 5-dose series when the Six by Seven rule applies.
Influenza Update
Updated wiki to reflect the 2024-2025 season. Influenza 2024-2025 Season rules remain unchanged from last season. Note: There are no evaluation and forecasting changes for the 2024-2025 season.
RSV Update
Added support for a new RSV Vaccine Group.
Added support for RSV Vaccine Group series:
RSV Infant Series: Seasonal series recommended for infants younger than 8 months of age
RSV Adult Series: Series recommended for adults age 75 years and older
Added support for RSV vaccines: CVX 303, CVX 304, CVX 305, CVX 306, CVX 307, CVX 314, CVX 315, CVX 326.
Modifications to the ICE Implementation Guide Codes Sheet to reflect the new vaccine group, new series, and new CVX codes.
8/19/2024: Release v2.43.1 / v1.43.1
Core Service Update
Updates the ICE service to Java 17, Tomcat 10, and OpenCDS v6. The transition to OpenCDS v6 also updates ICE to Spring v6.
Version 2.43.1 is functionally equivalent to version 1.43.1.
Release v1.43.1 continues to be available, and one subsequent v1 (Java 8/Tomcat 9) release will be made available to ensure users can successfully transition to v2 (Java 17/Tomcat 10).
Note: There are no changes to the ICE Implementation Guide or the ICE Implementation Guide Codes sheet for this release.
6/21/2024: Release v1.43.1
Meningococcal B Update
Updated ICE to support CVX 316 (Meningococcal MenABCWY (Penbraya)) in the Meningococcal B Vaccine Group.
Addressed an issue in the Meningococcal B Vaccine Group - Series Selection Rules that resulted in (under certain circumstances) the incorrect series being selected.
Meningococcal ACWY Update
Updated ICE to support CVX 316 (Meningococcal MenABCWY (Penbraya)) in the Meningococcal ACWY Vaccine Group.
DTP Update
Added recommendation reason codes ADMINISTER_TDAP_OR_TD and SUPPLEMENTAL_TEXT, descriptive Text: "Administer either Tdap or Td" associated with the vaccine group-level recommendation for the recurring booster dose. Given the recurring booster dose recommendation is at the vaccine group level (DTP), this additional information helps clarify the recommendation.
Influenza Update
Added support for CVX 320, Influenza, MDCK, trivalent, preservative.
MMR Update
Addressed an issue where ICE was not counting a reported indication of immunity when a patient receives one dose of MMR followed by antigens.
Varicella Update
Addressed an issue where ICE was not returning the correct forecast if 2 or more proof of immunity or 2 or more diseases were documented.
Hep A / Hep B Update
Addressed an issue where ICE was not returning the correct forecast if 2 or more proof of immunity were documented.
Other
A new property, disable_covid19_sep2023_dose_number_reset, was added to the ice.properties file. If enabled, ICE will not reset the dose number to 1 when recommending the Sept 2023 COVID-19 >= 5y series. This option is disabled by default, aligning with the behavior in the last version.
3/18/2024: Release v1.42.1.4
Fixes a COVID-19 dose numbering issue to support incrementing of dose number for patients who did not complete a < 5 years series prior to 9/12/2023 and are continuing in a < 5 years series.
Clarification to a COVID-19 Sept 2023 COVID-19 Series (>= 5 years) series special rule and corresponding logic update to address an exception related to handling CVX 313 in the >= 5 years series.
Extends the "start" date for COVID-19 vaccine from 12/01/2020 to 1/01/1970 to prevent COVID-19 shots administered prior to 12/01/2020 from being assigned to the "Other" vaccine group.
3/07/2024: Release v1.42.1.3
Fixes an issue discovered in v1.42.1.2. In certain situations, some historical COVID doses prior to September 12, 2023 were being evaluated as Accepted rather than Valid. This release fixes this issue.
3/05/2024: Release v1.42.1.2
Fixes an issue discovered in v1.42.1 where some shots in the COVID-19 >= 5yr series were incorrectly being marked as Invalid.
3/01/2024: Release v1.42.1
COVID-19 - September 2023 Onwards
Added support for COVID-19 recommendations introduced on September 12, 2023. These recommendations are supported by an additional set of logic for the COVID-19 Vaccine Group, COVID-19 Seasonal Vaccine Group.
Added support for five new series:
Sept 2023 COVID-19 Series (>= 5 years),
Sept 2023 Pfizer COVID-19 Series (< 5 years),
Sept 2023 Moderna COVID-19 Series (< 5 years),
Sept 2023 Mixed Product COVID-19 Series (< 5 years), and
Sept 2023 Novavax COVID-19 Series.
Added support for the updated (2023–2024 formula) COVID-19 vaccines: CVX 308, CVX 309, CVX 310, CVX 311, CVX 312, and CVX 313.
COVID-19 Vaccine Group Rule Sets
COVID-19 shots administered before 9/12/2023 are evaluated according to the logic specified in the COVID-19 Pandemic Vaccine Group wiki. Shots administered on or after 9/12/2023 are evaluated according to the logic specified in the new COVID-19 Seasonal Vaccine Group wiki.
The two COVID-19 Vaccine Group rule sets are designed to work with one another, with prior history (i.e., before 9/12/2023) influencing current recommendations, as per the ACIP and CDC guidelines.
11/03/2023: Release v1.41.1
Pneumococcal
Added support for PCV20 (CVX 216) use in children, with the following changes in the Pneumococcal Child Series:
Lowered the absolute minimum age of CVX 216 from 18 years - 4 days to 6 weeks - 4 days.
Incorporated CVX 216 as a valid CVX code per dose.
The CVX 216 changes are in the Pneumococcal Child Series only. In a future release, HLN will refine the logic for handling of CVX 216 administered between the ages of 6 and 19 years when intended for the adult series.
Note: There are no changes to the ICE Implementation Guide.
10/06/2023: Release v1.40.1
General Rule - Live Vaccine Interval